Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5-pyridinedicarboxylates

A group of racemic 3-[(2-nitrooxyethyl), (3-nitrooxypropyl), (4-nitrooxybutyl) or (1,3-dinitrooxy-2-propyl)], 5-methyl (ethyl or propyl) 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5-pyridinedicarboxylates ( 18– 29) were synthesized using modified Hantzsch reaction that involved the...

Full description

Saved in:
Bibliographic Details
Published in:Farmaco (Società chimica italiana : 1989) Vol. 57; no. 2; pp. 123 - 128
Main Authors: Miri, Ramin, Niknahad, H, Vesal, Gh, Shafiee, A
Format: Journal Article
Language:English
Published: France Elsevier SAS 01-02-2002
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A group of racemic 3-[(2-nitrooxyethyl), (3-nitrooxypropyl), (4-nitrooxybutyl) or (1,3-dinitrooxy-2-propyl)], 5-methyl (ethyl or propyl) 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3,5-pyridinedicarboxylates ( 18– 29) were synthesized using modified Hantzsch reaction that involved the condensation of 2-nitrooxyethyl ( 8), 3-nitrooxypropyl ( 9), 4-nitrooxybutyl ( 10) or 1,3-dinitrooxy-2-propyl ( 13) acetoacetate with methyl ( 14), ethyl ( 15) or isopropyl ( 16) 3-aminocrotonate and 1-methyl-5-nitroimidazole-2-carboxaldehyde ( 17). In vitro calcium channel antagonist activities were determined using a guinea pig ileum longitudinal smooth muscle assay. Compounds 18– 29 exhibited superior, or equipotent, calcium antagonist activity (IC 50=10 −11–10 −13 M range) relative to the reference drug nifedipine (IC 50=1.07±0.12×10 −11 M), which could serve as potential probes to investigate the in vivo release of nitric oxide which induces vascular muscle relaxation.
ISSN:0014-827X
1879-0569
DOI:10.1016/S0014-827X(01)01183-1